We found that the efficacy of first-line TKI was similar among three EGFR-positive NSCLC subtypes, suggesting that TKI should still be considered as a first-line regimen in all naïve EGFR-positive NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.